The CB1 receptor antagonist rimonabant was effective for obesity and smoking cessation but caused serious psychiatric side effects including depression and suicidal ideation, prompting new strategies like neutral antagonists and peripherally restricted drugs.
People interested in the intersection of cannabis science and obesity/addiction treatment.
Rimonabant withdrawn due to suicidal ideation risk
What the researchers found
Rimonabant demonstrated effectiveness for treating obesity and smoking cessation but was withdrawn from the European market due to psychiatric side effects. Researchers are now pursuing neutral antagonists, peripherally restricted ligands, and allosteric modulators to avoid these risks.
Why it matters
The CB1 receptor remains one of the most promising drug targets for obesity and addiction, but the failure of rimonabant showed that blocking it in the brain carries serious mental health risks. New approaches could unlock the therapeutic potential without the danger.
The numbers in context
Rimonabant was the first-in-class CB1R antagonist. It was withdrawn from the European market after reports of anxiety, depression, and suicidal ideation.
How the study worked
Narrative review of two decades of research on CB1 receptor-targeted therapeutics, covering animal and human studies of various drug development strategies.
What this study cannot tell us
This is a narrative review, not a systematic review. Some of the newer drug strategies discussed were still in preclinical stages at the time of writing.
How to read the evidence
Moderate: narrative review covering extensive preclinical and clinical evidence, though newer strategies lack human trial data.
When this study was published
Published in 2019.
The bigger picture
This story illustrates a broader challenge in cannabinoid medicine: the endocannabinoid system is deeply intertwined with mood regulation, so any drug targeting it must account for psychiatric consequences.
Questions still open
- Can peripherally restricted CB1 antagonists deliver meaningful weight loss without crossing into the brain? Will allosteric modulators prove safe enough for long-term use?
Common questions
What is rimonabant?
What does "peripherally restricted" mean?
Read the original research
Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.
Current topics in medicinal chemistry, 19(16), 1418-1435
Citation
Nguyen, Thuy; Thomas, Brian F; Zhang, Yanan. (2019). Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.. Current topics in medicinal chemistry, 19(16), 1418-1435. https://doi.org/10.2174/1568026619666190708164841
Explore the wider topic
- Physical vs Psychological Cannabis Dependence: What Science Actually Shows
- The Gap Between Cannabis Perception and Science: Why What We Believe Outpaces What We Know
- Cannabis Use Disorder: Am I Addicted? Self-Assessment Guide
- Cross-Addiction After Quitting Weed: When One Habit Replaces Another
- Is Weed Addictive? What the Research Actually Shows
- Is Cannabis Addictive? What the DSM-5 and Brain Science Say
- Quitting Weed and Alcohol Together: What to Know About Dual Cessation
- Is Rehab Necessary for Weed? An Honest Assessment
- Signs You May Have Cannabis Use Disorder: An Honest Self-Assessment
- Weed Vape Pen Addiction: Why Vaping Makes It Harder to Quit